Publication Name	World Journal of Stem Cells
Manuscript ID	54955
Country	India

Received	2020-02-26 11:56
Peer-Review Started	2020-02-26 11:56
To Make the First Decision
Return for Revision	2020-04-26 21:15
Revised	2020-05-09 14:22
Second Decision	2020-05-27 09:47
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2020-05-28 21:45
Articles in Press	2020-05-28 21:45
Publication Fee Transferred
Edit the Manuscript by Language Editor	2020-06-05 05:49
Typeset the Manuscript	2020-07-24 08:41
Publish the Manuscript Online	2020-07-26 08:24

ISSN	1948-0210 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Cell Biology
Manuscript Type	Review
Article Title	Potential of transposon-mediated cellular reprogramming towards cell-based therapies
Manuscript Source	Invited Manuscript
All Author List	Dharmendra Kumar, Taruna Anand, Thirumala R Talluri and Wilfried A Kues
Funding Agency and Grant Number
Corresponding Author	Dharmendra Kumar, PhD, Senior Scientist, Animal Physiology and Reproduction Division, ICAR-Central Institute for Research on Buffaloes, Grass Farm Road, Hisar 125001, India. dharmendra.kumar@icar.gov.in
Key Words	Transposons; Induced pluripotent stem cells; Clinical applications; Cellular reprogramming; Cell-based therapy; Genetic correction
Core Tip	Seminal discovery of induced pluripotent stem (iPS) cells have opened up the possibility of converting most somatic cell types into a pluripotent state. The iPS cells possess most of the advantages of embryonic stem cells without the ethical stigma associated with derivation of the latter. This procedure has had a large impact on generation of custom-made pluripotent cells, ideal for cell-type specific differentiation and regenerative medicine with or without genetic correction. In this review, we focus on updated information of transposon system-mediated cellular reprogramming to iPS cells and their application in cellular therapy.
Publish Date	2020-07-26 08:24
Citation	Kumar D, Anand T, Talluri TR, Kues WA. Potential of transposon-mediated cellular reprogramming towards cell-based therapies. World J Stem Cells 2020; 12(7): 527-544
URL	https://www.wjgnet.com/1948-0210/full/v12/i7/527.htm
DOI	https://dx.doi.org/10.4252/wjsc.v12.i7.527

Full Article (PDF)	WJSC-12-527.pdf
Full Article (Word)	WJSC-12-527.docx
Manuscript File	54955-Review-Webster J.docx
Answering Reviewers	54955-Answering reviewers.pdf
Audio Core Tip	54955-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	54955-Conflict-of-interest statement.pdf
Copyright License Agreement	54955-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	54955-Language certificate.pdf
Peer-review Report	54955-Peer-review(s).pdf
Scientific Misconduct Check	54955-Scientific misconduct check.pdf
Scientific Editor Work List	54955-Scientific editor work list.pdf